Tag: cardiovascular innovation

Identifying Risk Factors for Native Coronary Atherosclerosis Progression After Percutaneous Coronary Intervention

Identifying Risk Factors for Native Coronary Atherosclerosis ProgressionAnnouncing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at investigating factors influencing the progression of native coronary atherosclerosis after percutaneous coronary intervention (PCI).

A cohort of 462 patients was classified into progressive (n = 73) or non-progressive (n = 389) groups according to the presence of native coronary atherosclerosis progression on coronary angiography. Clinical data and angiography results were compared during follow-up, and the time to progression of native coronary atherosclerosis was recorded. Subsequently, multivariate Cox regression analysis was conducted.

In comparison to the non-progressive group, the progressive group had higher levels of glycosylated hemoglobin (HbA1c) and triglycerides (TG), and higher scores on the Synergy Between PCI with Taxus and Cardiac Surgery (SYNTAX) scale, but lower levels of high-density (more…)

Loading

Feasibility of an Integrated Digital and Pharmacological Approach Targeting Blood Lipids in Atherosclerotic Cardiovascular Disease Management

Announcing a new article publication for Cardiovascular Innovations and Applications journal.     Strong evidence supports the importance of lipid-lowering and exercise therapies in the long-term therapy of atherosclerotic cardiovascular disease (ASCVD). Establishing efficient comprehensive intervention programs that combine pharmacological and exercise prescription is crucial to investigate with the aid of digital technologies.

A convenience sample of 25 ASCVD patients (57.8 ± 9.5 years, 76% males) was gathered. All participants were prescribed with 12-week home exercise program supervised by an app and bimonthly 75mg alirocumab subcutaneous injections. Follow up visits were scheduled at the end of 4th and 12th week.

Nineteen participants completed the program with a retention rate of 76%. Sixteen (84.2%) participants received all six doses of alirocumab. The total management time of the 12-week program added up to 65.47 minutes per patient. Satisfaction score was 4.2 ± 0.6 and the User Version of the Mobile Application Rating Scale (uMARS) overall objective quality score on the app was 3.4 ± 0.7. At the 4-week and 12-week follow-ups, LDL-C levels reduced compared to baseline (−1.5 ± 0.8 mmol/L, P < 0.001, −1.6 ± 0.8 mmol/L, P < 0.001, respectively), along with TC (−1.8 ± 1.2 mmol/L, P < 0.001, −1.6 ± 1.3 mmol/L, P < 0.001, respectively), but not TG, HDL-C, GAD-7 and PHQ-9.

The integrated pharmaceutical and digital ERx intervention program was feasible and well accepted in ASCVD patients.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0002

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Xu Yi, Qiu Weiyu and Li Yan et al. Feasibility of an Integrated Digital and Pharmacological Approach Targeting Blood Lipids in Atherosclerotic Cardiovascular Disease Management. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2024.0002

Loading